TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07403968: An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib (TAK-279) in Participants With Active Crohn's Disease

Sponsor: Takeda · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,278,500

Rescue Site Savings

+$3,484,500

Unlock Full NCT07403968 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07403968 Rescue Dossier →